Diagnosis, pathogenesis and treatment of myositis: recent advances.
Carstens PO, Schmidt J.
Clin Exp Immunol. 2014 Mar;175(3):349-58. doi: 10.1111/cei.12194.
Immune Checkpoint Inhibitor-induced Myositis.
Jayan A, Mammen AL, Suarez-Almazor ME.
Rheum Dis Clin North Am. 2024 May;50(2):281-290. doi: 10.1016/j.rdc.2024.02.003. Epub 2024 Mar 12.
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ.
Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18.
Myositis Antibodies and Interstitial Lung Disease.
Basuita M, Fidler LM.
J Appl Lab Med. 2022 Jan 5;7(1):240-258. doi: 10.1093/jalm/jfab108.
Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.
Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, Senécal JL, Geny B, Landon-Cardinal O, Meyer A.
Front Immunol. 2023 Jan 26;13:974078. doi: 10.3389/fimmu.2022.974078. eCollection 2022.
Giant cell myositis and myocarditis revisited.
Oflazer P.
Acta Myol. 2020 Dec 1;39(4):302-306. doi: 10.36185/2532-1900-033. eCollection 2020 Dec.
Update on Myositis Therapy: From Today's Standards to Tomorrow's Possibilities.
Glaubitz S, Zeng R, Rakocevic G, Schmidt J.
Curr Pharm Des. 2022;28(11):863-880. doi: 10.2174/1381612827666211115165353.
Interstitial lung disease and myositis.
Gono T, Kuwana M.
Curr Opin Rheumatol. 2024 Nov 1;36(6):466-472. doi: 10.1097/BOR.0000000000001037. Epub 2024 Aug 12.
Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.
Hallowell RW, Paik JJ.
Clin Exp Rheumatol. 2022 Feb;40(2):373-383. doi: 10.55563/clinexprheumatol/brvl1v. Epub 2021 Mar 25.
Myositis non-inflammatory mechanisms: An up-dated review.
Manole E, Bastian AE, Butoianu N, Goebel HH.
J Immunoassay Immunochem. 2017;38(2):115-126. doi: 10.1080/15321819.2017.1298525.
